AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Silverback therapeutics logo12/18/2023 ![]() ![]() In April 2021, Silverback presented data at the American Association of Cancer Dosing has been initiated in the GLP toxicology study and GMP manufacturing of the Phase 1 clinical supply is underway. GLP toxicology studies have commenced for SBT6290 (Nectin4-TLR8 ImmunoTAC), with an IND submissionĪnticipated in the fourth quarter of 2021. Silverback is on track to deliver interim clinical data from the monotherapy dose escalation arm of the study in the second half of 2021. SBT6050 (HER2-TLR8 ImmunoTAC) continues to advance through monotherapy and pembrolizumab combination doseĮscalation arms of the Phase 1/1b clinical study. Year, and we are equally excited about the progress and preclinical data emerging from SBT6290 and SBT8230, highlighting the broad applicability of our ImmunoTAC platform. We are on track to report interim clinical data for SBT6050 in the second half of this On Silverbacks mission to bring tissue-targeted therapies to patients in need, said Laura Shawver, Ph.D., chief executive officer of Silverback. ![]() In our first quarter as a public company, our team continues to execute The first quarter ended March 31, 2021 and provided a business update. (Nasdaq: SBTX) (Silverback), a clinical-stage biopharmaceuticalĬompany leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today reported financial results for SEATTLE May 13, 2021 Silverback Therapeutics, Inc. Silverback Therapeutics Reports First Quarter 2021 Financial Results ![]()
0 Comments
Read More
Leave a Reply. |